{
  "status_code": 200,
  "request": {
    "criteria": [
      {
        "name": "Disease",
        "type": "exclude",
        "value": "Other diseases"
      },
      {
        "name": "Disease",
        "type": "exclude",
        "value": "Early stage cancer"
      },
      {
        "name": "Population",
        "type": "exclude",
        "value": "Laboratory studies"
      },
      {
        "name": "Population",
        "type": "exclude",
        "value": "Animal studies"
      },
      {
        "name": "Population",
        "type": "exclude",
        "value": "Drug discovery studies"
      },
      "\u202645 more"
    ],
    "project_description": "Comprehensive genomic profiling/NGS in solid cancers.",
    "research_questions": [
      "What is the incidence and prevalence of advanced cancers in Europe and other key jurisdictions?\n-   Focus on France, Italy, Spain, Belgium, Switzerland, UK; also include data for rest of Europe and Brazil, Chile, Columbia, Mexico, Canada.",
      "What are EMA-approved and ESMO guideline-recommended biomarker-guided treatments in advanced cancer types?\n-   Focus on the use of genomic testing in non-small-cell lung cancer, colorectal cancer, malignant melanoma, ovarian cancer and breast cancer, to reflect the different number and type of biomarkers associated with each type of malignant disease",
      "What are the types of precision medicine approaches in advanced cancers in Europe (that is, finding treatments that are effective for specific genomic biomarkers in a solid tumor)?\n-   Targeted therapies for specific cancer types\n-   Tissue-agnostic (pan-cancer) therapies\n-   Multi-tumor type targeted therapies\n-   Biomarker-based immunotherapy approaches\n-   Emerging molecularly targeted therapies and ongoing clinical trials",
      "What are the unmet needs with current practice of genomic testing in advanced cancers in Europe?\n-   What are the existing technologies for genomic testing?\n-   What are the technology requirements for identification of specific types of genomic aberrations?\n-   What are the key unmet needs in genomic testing workup approaches in current clinical practice?\n-   What are the challenges faced by people trying to implement genomic testing for rate mutations?",
      "What is the clinical utility of comprehensive genome profiling (CGP)?\n-   How far does CGP offer broader coverage of medically necessary biomarkers than more traditional methods of identifying mutations, such as polymerase chain reaction (PCR), chromosomal microarray (CMA) \u00c2\u00a0or small gene panel assays?\n-   Is the accuracy of CGP higher than traditional approaches in detecting biomarkers?\n-   Does the use of CGP improve patient outcomes, for example, do patients respond better to, or live longer with, therapies that target the patient's specific mutation?\n-   Does the use of CGP mean that fewer biopsy samples are needed?\n-   Does the use of CGP increase the number of patients who are eligible to be enrolled in clinical trials of new targeted therapies?",
      "Economic impact\n-   What is the budget impact of adopting CGP compared with traditional genetic testing?\n-   What is the cost-effectiveness of CGP?"
    ],
    "mock": true
  },
  "response": {
    "duplicate_groups": [],
    "consolidation_proposals": [],
    "warnings": [
      "Mock mode: no consolidation performed"
    ]
  }
}